Vemurafenib is approved in more than 90 countries for the treatment of patients with BRAFV600‐mutated metastatic melanoma.1,2 In the pivotal BRIM‐3 trial, treatment‐emergent cutaneous side effects were associated with vemurafenib, including the development of epithelial tumours and, in rare cases, new primary melanomas.3,4 QTc interval prolongation and hepatic laboratory abnormalities were also noted.3,4 This article is protected by copyright. All rights reserved.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile